company background image
PPBT logo

Purple Biotech TASE:PPBT Stock Report

Last Price

₪0.063

Market Cap

₪32.5m

7D

-11.3%

1Y

-81.5%

Updated

21 Dec, 2024

Data

Company Financials +

Purple Biotech Ltd

TASE:PPBT Stock Report

Market Cap: ₪32.5m

PPBT Stock Overview

A clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. More details

PPBT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap (₪33M)

Makes less than USD$1m in revenue ($0)

Earnings have declined by 1.3% per year over past 5 years

Highly volatile share price over the past 3 months compared to the IL market

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Purple Biotech Ltd Competitors

Y.B Urban Renewal - Residential Development

TASE:YBRD

₪32.5m

Tikun Olam-Cannbit Pharmaceuticals

TASE:TKUN

₪30.7m

Seach Medical Group

TASE:SEMG

₪105.7m

Rekah Pharmaceutical Industry

TASE:REKA

₪158.9m

Price History & Performance

Summary of share price highs, lows and changes for Purple Biotech
Historical stock prices
Current Share Price₪0.063
52 Week High₪0.37
52 Week Low₪0.043
Beta0.33
1 Month Change28.57%
3 Month Change-52.27%
1 Year Change-81.47%
3 Year Change-95.15%
5 Year Change-97.47%
Change since IPO-99.97%

Recent News & Updates

Recent updates

We're A Little Worried About Purple Biotech's (TLV:PPBT) Cash Burn Rate

Mar 07
We're A Little Worried About Purple Biotech's (TLV:PPBT) Cash Burn Rate

Can Purple Biotech (TLV:PPBT) Afford To Invest In Growth?

Oct 30
Can Purple Biotech (TLV:PPBT) Afford To Invest In Growth?

Will Purple Biotech (TLV:PPBT) Spend Its Cash Wisely?

Jul 17
Will Purple Biotech (TLV:PPBT) Spend Its Cash Wisely?

Here's Why We're Watching Purple Biotech's (TLV:PPBT) Cash Burn Situation

Mar 13
Here's Why We're Watching Purple Biotech's (TLV:PPBT) Cash Burn Situation

Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?

Nov 27
Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?

Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?

Jul 21
Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?

Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans

Mar 25
Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans

Companies Like Purple Biotech (TLV:PPBT) Are In A Position To Invest In Growth

Dec 09
Companies Like Purple Biotech (TLV:PPBT) Are In A Position To Invest In Growth

Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans

May 28
Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans

We Think Purple Biotech (TLV:PPBT) Can Afford To Drive Business Growth

Feb 11
We Think Purple Biotech (TLV:PPBT) Can Afford To Drive Business Growth

If You Had Bought Purple Biotech's (TLV:KTOV) Shares Five Years Ago You Would Be Down 90%

Dec 21
If You Had Bought Purple Biotech's (TLV:KTOV) Shares Five Years Ago You Would Be Down 90%

Shareholder Returns

PPBTIL PharmaceuticalsIL Market
7D-11.3%0.9%-0.5%
1Y-81.5%-12.2%23.0%

Return vs Industry: PPBT underperformed the IL Pharmaceuticals industry which returned -12.2% over the past year.

Return vs Market: PPBT underperformed the IL Market which returned 23% over the past year.

Price Volatility

Is PPBT's price volatile compared to industry and market?
PPBT volatility
PPBT Average Weekly Movement35.8%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.2%
10% most volatile stocks in IL Market8.0%
10% least volatile stocks in IL Market3.0%

Stable Share Price: PPBT's share price has been volatile over the past 3 months compared to the IL market.

Volatility Over Time: PPBT's weekly volatility has increased from 21% to 36% over the past year.

About the Company

FoundedEmployeesCEOWebsite
196820Gil Efronpurple-biotech.com

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.

Purple Biotech Ltd Fundamentals Summary

How do Purple Biotech's earnings and revenue compare to its market cap?
PPBT fundamental statistics
Market cap₪32.54m
Earnings (TTM)-₪42.43m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Is PPBT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PPBT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$196.00k
Gross Profit-US$196.00k
Other ExpensesUS$11.46m
Earnings-US$11.66m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.023
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PPBT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 00:58
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Purple Biotech Ltd is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.
Raghuram SelvarajuRodman & Renshaw, LLC